Reference

Antiviral agents containing acyclovir, fusaric acid and derivatives

Antiviral agents containing acyclovir, fusaric acid and derivatives. Amin, Avinash N.; Douglas, Michael G.In this study， 104227-87-4 and 30516-87-1 are also used. (Novactyl, Inc., USA). PCT Int. Appl. WO 2003006062 A1 23 Jan 2003, 41 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K045-06. ICS: A61P031-12. APPLICATION: WO 2001-US22228 11 Jul 2001. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Section cross-reference(s): 63 Compns. are provided, which are comprised of at least one nucleoside analog inhibitor, pharmaceutically acceptable salts, solvates, or prodrugs and fusaric acid, derivs., or pharmaceutically acceptable salts thereof. Pharmaceutical compns. comprising the above compns. are also provided that optionally further include another therapeutically effective compd., such as a carrier. Systemic and topical prepns. comprising the above compns. are also provided as well as methods of treating viral diseases by the administration of the above antiviral agents to a patient. Fusaric acid 10 mg/mL combined with acyclovir enhanced acyclovir antiviral effects while fusaric acid alone had no effect on both HSV-1 and -2 in a plaque redn. assay. .

Determination of penciclovir in human plasma using LC with fluorescence detection: application to a bioequivalence study

All Rights Reserved. Determination of penciclovir in human plasma using LC with fluorescence detection: application to a bioequivalence study. Zhou, Quan; Ruan, Zourong; Yuan, Hong; Jiang, Bo; Xu, Donghang; Lou, Honggang (Division of Clinical Pharmacology, The 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, Peop. Rep. 39809-25-1 and 104227-87-4 are also occured in this study. China). Chromatographia, 64(9-10), 571-575 (English) 2006 Vieweg Verlag/GWV Fachverlage GmbH. CODEN: CHRGB7. ISSN: 0009-5893. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) A novel HPLC method with fluorescence detection and 1 step sample prepn. was developed for the detn. of penciclovir in human blood plasma. Plasma samples (200 mL) were deproteinized by pptn. with 100 mL of perchloric acid and centrifuged. Sepn. was on an Inertsil ODS-3 column with a mixt. of methanol-0.1% orthophosphoric acid as mobile phase. The fluorescence detector was set at Ex 270 nm, Em 375 nm. The assay was selective and linear with a limit of quantification of 0.025 mg L-1. The mean abs. recovery was 98.1%, while the intra- and inter-day coeffs. of variation and percent error values of the assay method were all < 10%. The assay was successfully applied in a randomized cross-over bioequivalence study of 3 pharmaceutical products contg. 250 mg famciclovir (an oral prodrug of penciclovir) in 18 healthy volunteers. .